<DOC>
	<DOCNO>NCT01236053</DOCNO>
	<brief_summary>High dos gabapentin associate pancreatic acinar cell tumor rat , post marketing pancreatic carcinogenicity signal gabapentin report spontaneous report AERS publish literature . In publish case-control screen study association gabapentin 55 cancer , cancer meet screen criterion possibly increase cancer risk gabapentin exposure renal ( include renal pelvis ) cancer . This association judge likely due substantially accentuate confound cigarette smoking , hypertension , lifestyle ( Cancer Causes Control 2009 ; 20:1821-1835 ) . The relationship gabapentin exposure pancreatic cancer renal cancer study NCT01138124 , supplemental analyse cancer perform current study . The FDA recommend GSK also study relationship gabapentin all-cancer site , well cancer follow specific site : 1 ) stomach , 2 ) anus , anal canal , anorectum , 3 ) lung bronchus , 4 ) bone joint , 5 ) breast , 6 ) penis , 7 ) urinary bladder , 8 ) nervous system . The primary objective study determine whether exposure gabapentin associate increase risk develop all-cancer , specific cancer United Kingdom ( UK ) General Practice Research Database ( GPRD ) . Each member UK population register General Practice , centralize medical information general practitioner also specialist referral hospital attendance . Over 487 General Practices contribute data GPRD . The study cohort case control drawn subject GPRD 1993-2008 . Gabapentin approve UK May 1993 . Entry study cohort begin Jan 1 , 1993 register GPRD time , time registration later Jan 1 , 1993 . Subjects exclude GPRD cohort cancer diagnosis history cancer prior cohort entry date . Patients first diagnosis respective cancer 1995-2008 risk set match 10 control within General Practice age cohort entry ( within two year ) , sex , year entry study cohort ( within one year ) . For case , index date date first diagnosis respective cancer . The index date control set date follow-up time cohort entry case . The index date choose give control equal follow-up time case ascertainment use gabapentin . Cases control require least 2 year follow-up study cohort index date . Cases must history cancer diagnosis prior index date . Controls require free cancer diagnosis database control 's index date . Data gabapentin prescription obtain case control study cohort entry index date . Gabapentin exposure assess ever/never , number prescription , cumulative dose , cumulative duration , 2 year lag period incorporate control protopathic bias ( gabapentin prescription initial pain symptom undiagnosed cancer ) latency ( time cancer onset specific GPRD cancer diagnosis ) . Crude adjust odds ratios 95 % confidence interval ( CI ) produce conditional logistic regression model , additional analysis evaluate dose-response . Covariates include indication gabapentin use risk factor cancer .</brief_summary>
	<brief_title>Cancer Patients With Gabapentin ( GPRD )</brief_title>
	<detailed_description>Actual number patient may less , possible patient represent one 22 arm ( See `` Participant Flow : Overall Study '' Table ) risk set sampling .</detailed_description>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Urinary Bladder Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Pancreatitis</mesh_term>
	<mesh_term>Kidney Neoplasms</mesh_term>
	<mesh_term>Anus Neoplasms</mesh_term>
	<mesh_term>Pancreatitis , Chronic</mesh_term>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Pelvic Neoplasms</mesh_term>
	<mesh_term>Neuralgia</mesh_term>
	<mesh_term>Nervous System Neoplasms</mesh_term>
	<mesh_term>Penile Neoplasms</mesh_term>
	<mesh_term>Gabapentin</mesh_term>
	<mesh_term>gamma-Aminobutyric Acid</mesh_term>
	<criteria>The study cohort case control drawn subject UK GPRD 19932008 . Entry study cohort begin Jan 1 , 1993 register GPRD time , time registration later Jan 1 , 1993 . Followup end Dec 31 , 2008 , earlier subject leave GPRD reason include death . Subjects exclude GPRD cohort cancer diagnosis history cancer prior cohort entry date . Cases control require least 2 year followup study cohort index date ( For case , index date date first diagnosis respective cancer . The index date control set date followup time cohort entry case . ) Cases must history cancer diagnosis prior index date . Controls require free cancer diagnosis database control 's index date .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2012</verification_date>
	<keyword>renal cancer</keyword>
	<keyword>pancreatic cancer</keyword>
	<keyword>epidemiology</keyword>
	<keyword>renal cell carcinoma</keyword>
	<keyword>nervous system cancer</keyword>
	<keyword>lung cancer</keyword>
	<keyword>breast cancer</keyword>
	<keyword>case-control</keyword>
	<keyword>GPRD</keyword>
	<keyword>Gapabentin</keyword>
	<keyword>cancer</keyword>
	<keyword>anal cancer</keyword>
	<keyword>bone joint cancer</keyword>
	<keyword>renal pelvis cancer</keyword>
	<keyword>penis cancer</keyword>
	<keyword>stomach cancer</keyword>
	<keyword>bladder cancer</keyword>
</DOC>